Patents by Inventor Marc Korn

Marc Korn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIM-3 Kinase as a Target for Type 2 Diabetes Mellitus
    Publication number: 20140087969
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: November 7, 2013
    Publication date: March 27, 2014
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Marc KORN, Guenter MUELLER, Rudolf SCHNEIDER, Georg TSCHANK
  • PIM-3 kinase as a target for type 2 diabetes mellitus
    Patent number: 8580251
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: November 12, 2013
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
  • PIM-3 KINASE AS A TARGET FOR TYPE 2 DIABETES MELLITUS
    Publication number: 20100041058
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: October 19, 2009
    Publication date: February 18, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Marc KORN, Guenter MUELLER, Rudolf SCHNEIDER, Georg TSCHANK
  • PIM-3 kinase as a target for type 2 diabetes mellitus
    Patent number: 7629126
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: December 8, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
  • PIM-3 KINASE AS A TARGET FOR TYPE 2 DIABETES MELLITUS
    Publication number: 20070154919
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: December 12, 2006
    Publication date: July 5, 2007
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
  • PIM-3 kinase as a target for type 2 diabetes mellitus
    Publication number: 20040038246
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: January 21, 2003
    Publication date: February 26, 2004
    Inventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank